Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (H. pylori). Pantoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
**Standard Regimen:**
* Pantoprazole 40 mg orally twice daily
* Amoxicillin 1000 mg orally twice daily
* Clarithromycin 500 mg orally twice daily
This regimen is typically prescribed for 7 to 14 days.
## Pediatric Dosing
Pediatric dosing for Sompraz HP is not established. Dosing of individual components may be considered in consultation with a pediatrician or infectious disease specialist.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment for pantoprazole is recommended in mild to moderate renal impairment. In severe renal impairment, caution is advised. Amoxicillin and clarithromycin doses may require adjustment based on renal function; consult specific prescribing information for these agents.
* **Hepatic Impairment:** In patients with severe hepatic impairment, the maximum dose for pantoprazole is 20 mg once daily.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or other macrolides.
* History of severe hypersensitivity to penicillin or cephalosporin antibiotics.
* Concomitant use with rifabutin, rifampin, or other potent CYP3A4 inducers (due to clarithromycin).
* Use in patients with a history of cholestatic hepatitis or hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, headache, taste disturbance, rash.
* **Serious:** *Clostridium difficile*-associated diarrhea, hypersensitivity reactions, severe skin reactions (e.g., Stevens-Johnson syndrome), QT prolongation (especially with clarithromycin), liver dysfunction, peripheral neuropathy, seizures.
## Key Drug Interactions
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
* **CYP2C19 Substrates (e.g., clopidogrel, voriconazole):** Pantoprazole can inhibit CYP2C19, potentially increasing concentrations of these drugs.
* **CYP3A4 Substrates (e.g., simvastatin, cyclosporine, tacrolimus):** Clarithromycin is a potent inhibitor of CYP3A4 and can increase concentrations of these drugs.
* **Digoxin:** Increased digoxin levels, potentially leading to toxicity.
* **Moclobemide:** Increased risk of serotonin syndrome.
## Monitoring
* Assess for signs and symptoms of H. pylori eradication (e.g., resolution of ulcer symptoms, negative urea breath test or stool antigen test after treatment).
* Monitor for adverse effects, particularly diarrhea, rash, and signs of liver dysfunction.
* Monitor INR if patient is also taking warfarin.
## Clinical Pearls
* Administer the full course of therapy as prescribed to ensure eradication of H. pylori and prevent resistance.
* Pantoprazole should be taken at least 30 minutes before meals.
* Amoxicillin and clarithromycin should be taken with food or milk to minimize gastrointestinal upset.
* Patients with penicillin allergy may be candidates for alternative H. pylori eradication regimens.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for definitive patient care decisions.
